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Abstract
Simple and cost-effective approaches for HIV drug-resistance testing are highly desirable for managing increasingly
expanding HIV-1 infected populations who initiate antiretroviral therapy (ART), particularly in resource-limited settings. Non-
nucleoside reverse trancriptase inhibitor (NNRTI)-based regimens with an NRTI backbone containing lamivudine (3TC) or
emtricitabine (FTC) are preferred first ART regimens. Failure with these drug combinations typically involves the selection of
NNRTI- and/or 3TC/FTC- resistant viruses. Therefore, the availability of simple assays to measure both types of drug
resistance is critical. We have developed a high throughput screening test for assessing enzymatic resistance of the HIV-1 RT
in plasma to 3TC/FTC and NNRTIs. The test uses the sensitive ‘‘Amp-RT’’ assay with a newly-developed real-time PCR format
to screen biochemically for drug resistance in single reactions containing either 3TC-triphosphate (3TC-TP) or nevirapine
(NVP). Assay cut-offs were defined based on testing a large panel of subtype B and non-subtype B clinical samples with
known genotypic profiles. Enzymatic 3TC resistance correlated well with the presence of M184I/V, and reduced NVP
susceptibility was strongly associated with the presence of K103N, Y181C/I, Y188L, and G190A/Q. The sensitivity and
specificity for detecting resistance were 97.0% and 96.0% in samples with M184V, and 97.4% and 96.2% for samples with
NNRTI mutations, respectively. We further demonstrate the utility of an HIV capture method in plasma by using magnetic
beads coated with CD44 antibody that eliminates the need for ultracentifugation. Thus our results support the use of this
simple approach for distinguishing WT from NNRTI- or 3TC/FTC-resistant viruses in clinical samples. This enzymatic testing is
subtype-independent and can assist in the clinical management of diverse populations particularly in resource-limited
settings.
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Introduction
Antiretroviral therapy has significantly improved life expectancy
and quality of life in persons living with HIV [1]. Currently there
are 24 antiretroviral drugs approved by the US Food and Drug
Administration (FDA) for the treatment of HIV-1-infected
persons, including 11 reverse transcriptase (RT) inhibitors, 10
protease inhibitors, 1 fusion inhibitor, 1 entry inhibitor, and 1
integrase inhibitor. The selection of a combination regimen that
maximally suppresses virus replication is critical for treatment
success, since persistent virus replication due to suboptimal
therapy may result in the selection of viruses carrying drug-
resistance mutations. The emergence of drug-resistant viruses can
be one of the most important factors leading to therapy failure [2].
Accumulating data from various retrospective and prospective
studies support the use of drug-resistance testing in many clinical
situations, and several agencies and expert panels such as the
IAS-USA Panel [3], the EuroGuidelines Group for HIV Resistance
[4], and the U.S. Department of Health and Human Services
(http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf)
recommend drug-resistance testing for the management of
antiretroviral therapy.
NNRTI-based ART regimens containing efavirenz (EFV) or
nevirapine (NVP) are frequently used in first regimens worldwide.
These regimens typically include a nucleoside RT inhibitor
backbone containing either lamivudine (3TC) or the closely
related emtricitabine (FTC). Resistance to 3TC/FTC is primarily
associated with mutations at position 184 of the HIV-1 RT, in
which the wild-type (WT) Methionine (M) is frequently replaced
by Valine (V) and less commonly by Isoleucine (I). The presence of
the M184V mutation results in .100-fold decreased susceptibility
to both drugs [5,6]. EFV and NVP have overlapping resistance
profiles conferred by a number of mutations. K103N and Y188L
confer high-level resistance to NVP and EFV, while Y181C/I/V
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failure with NNRTI-containing regimens generally associates with
the emergence of NNRTI- and/or 3TC/FTC-resistant viruses
[10,11]. In one study of drug-naı ¨ve persons comparing EFV with
either Combivir (zidovudine/3TC) or Truvada (tenofovir and
FTC), treatment failures at 96 weeks had viruses that were more
commonly NNRTI-resistant or 3TC/FTC-resistant than tenofo-
vir- resistant [12]. Likewise Margot et al. found K103N as the
most common resistance mutation in patients failing regimens
containing tenofovir, FTC and efavirenz or zidovudine, 3TC and
EFV [13]. M184V and K103N/Y181C were seen in .10% of
patients failing antiretroviral therapy in British Columbia, Canada
during 1996 to 2003 [14]. Delaugerre et al. detected NNRTI-
associated mutations in more than 98% of patients failing an
efavirenz- or NVP-containing regimen [8].
Therefore, the availability of simple assays to measure
NNRTI or 3TC/FTC resistance can be highly useful for
managing first-line regimens. Rapid assays that can distinguish
WT from 3TC/FTC- or NNRTI- resistant virus during
virologic failure can inform decisions for switching regimens,
which is particularly important in resource-limited settings with
often single second-line regimens. Although sequencing is a
widely used genotypic test to monitor drug resistance in
resource-rich countries, the complexity and cost of this testing
limits its utility for resource-limited countries with large HIV-
infected populations. Thus, current treatment guidelines in
resource-limited countries do not include resistance testing. We
have previously described the use of a sensitive biochemical
assay (Amp-RT) to measure the enzymatic activity of reverse
transcriptase (RT) of HIV-1 in plasma and assess its suscepti-
bility to antiretroviral drugs [15]. Like other RT assays that are
broadly reactive on all retroviruses, Amp-RT can detect
generically RT activity from diverse retrovirus groups including
H I V - 1n o n - s u b t y p eBa n dH I V - 2[ 1 5 , 1 6 ] .W eh a v ep r e v i o u s l y
demonstrated that this technology can also be used for HIV
drug-resistance testing and have shown that biochemical
detection of NNRTI and 3TC resistance by this method
correlates well with genotypic and replication-based phenotypic
assays [9,17]. Here, we describe the development of improved
Amp-RT assays that use real-time PCR detection and simplified
virus capture from plasma. The real-time PCR readout replaces
the previously used ELISA-based detection of PCR products
and provides a rapid and cost-effective quantitation. Likewise
we demonstrate the utility of virus capture from plasma by
magnetic beads that eliminate the need for ultracentrifugation.
W ee v a l u a t e dA m p - R T - b a s e da s s a y s that screen for resistance to
3TC and NVP in a large collection of clinical specimens with
known drug-resistance profiles, and show data that support the
promise of this testing strategy for drug-resistance management.
Materials and Methods
Ethics Statement
Specimens were anonymous residual diagnostic material from
subjects who provided written consent for HIV testing. The CDC
Institutional Review Board determined that this testing did not
involve identifiable human subjects and has approved the study.
Assay Optimization
The optimization of assay conditions was done by unblinded
testing of 140 plasma samples. They consisted of 114 subtype B
and 26 non-B subtypes (two A, 22 recombinant AG, two
unknown). In addition, the specificity was evaluated by testing
160 samples from HIV- seronegative blood donors and 14
HIV-seropositive specimens that had undetectable RNA viral
loads (,40 copies/ml). Assay validation was done by blinded
testing 253 (229 subtype B, 14 subtype C, 6 subtype A, 1 subtype
D, and 3 recombinant including CRF nomenclatures AG and
AE) plasma samples collected at the BC Centre for Excellence in
HIV/AIDS (BC, Canada). The median RNA virus load in these
samples was 4.28+/20.84 log10 copies/ml and ranged between
2.29 and 5.88.
Viral load Measurement and Sequencing
Roche Amplicor Version 1.5, with a limit of detection of 50
copies/ml was used for quantitating HIV RNA in plasma.
Standard population-based sequencing was performed with a
limit of detection of approximately 20–30% for a minority
sequence variant as described in [18]. The region sequenced
typically covered codon 1 to 400 of the RT.
Reference Viruses and Drugs
The following isolates were used as control reference viruses in
each experiment: HXB2, xxBRUpitt, and HIV-1SUM 9 as WT
viruses; M184Vpitt as 3TC-resistant virus carrying the M184V
mutation [13]. X403-4 and X82-5 are NVP-resistant isolates
carrying the Y181C or K103N/Y181C mutations, respectively
[9]. Nevirapine was obtained from the NIH AIDS Research &
Reference Program (Rockville, MD). 3TC-triphosphate was
synthesized by Sierra Bioresearch (Tucson, AZ). Both drugs were
aliquoted and kept at 280uC.
Principle of the Amp-RT Assay
Amp-RT is an ultrasensitive RT assay that uses PCR to detect
RT-generated DNA of an exogenous non-retroviral heteropoly-
meric RNA template from the encephalomyocarditis virus
(EMCV) genome [15]. Levels of EMCV DNA generated by
HIV-1 RT in a plasma specimen are quantified by real-time PCR
as described below.
RT Activity Detection by Amp-RT
To detect RT activity in plasma specimens, 250 ml of plasma
was first clarified at 10,000 g for 5 min and then ultracentrifuged
at 99,000 g for 1 h at 4uC. Virus pellets were concentrated in a
final volume of 100 mlo f1 6RTCDR buffer (50 mM Tris HCl,
50 mM KCl, 10 mM MgCl2, 0.5 mM EGTA, 2 mM DTT,
0.06% NP-40). A known amount of HXB2 particles (1610
5)
spiked in an HIV-1 seronegative plasma was included in each
experiment to control for the quality of the ultracentrifugation
procedure. The mean and standard deviation were determined in
35 runs. The range for the control was defined as mean 636
standard deviation. Thus an individual ultracentrifugation run was
considered valid when the control with 1610
5 HXB2 particles
yielded a Ct value between 18.37 and 28.97.
To eliminate the need for ultracentrifugation, an alternative
method was evaluated for virus capture from plasma by using
magnetic beads coated with CD44 monoclonal antibody (mMulti-
MACS
TM VitalVirus HIV Isolation Kit; Miltenyi Biotec, Auburn,
CA). CD44 is one of the host cell proteins present on HIV l
particles [19]. CD44 been shown to be suitable for capture of
HIV-1 particless from patient samples [20] and can be used for
virus genotyping even from patients with no detectable viral load
[21]. After clarifying the plasma at 10,000 g for 5 min, 200 ml
were incubated with 20 ml microbeads for 10 min at room
temperature. Then, the mixture was applied to MACS separation
columns and washed 4 times. HIV-1 particles bound to the
column were dissolved in 100 ml1 6RTCDR, yielding HIV RT in
Rapid Resistance Testing for HIV RT Inhibitors
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RT reaction or stored at 270 uC.
Levels of RT activity were measured in duplicate using 96-well
plates. Briefly, 4 ml of virus pellets or eluants were added to 16 ml
of RT buffer containing 50 mM Tris HCl, 50 mM KCl, 10 mM
MgCl2, 0.5 mM EGTA, 2 mM DTT, 10 mM dCTP, 120 mM
dATP, dGTP, and dTTP, 1 mM antisense primer 262R (59-
CAACGTCTTCAAGCGTCGAAT-39), 0.20 ng 6 ml
21 EMCV
RNA, 0.10 u6ml
21 RNasin, and 0.06% NP-40. As a competitive
inhibitor, 3TC-TP inhibits RT activity more efficiently when
dCTP concentration is reduced resulting in less 3TC-TP in the
assay. We have previously shown by titrations of dCTP and 3TC-
TP that 10 mM of dCTP was optimal for detecting both RT
activity and its inhibition by 3TC-TP [17]. The RT reaction was
carried out for 2 h at 37uC, followed by a 5 min inactivation of
HIV-1 RT at 95uC. To evaluate the susceptibility of the RT for
3TC and NVP, parallel RT reactions were done in the presence of
50 mM 3TC-triphosphate (3TC-TP) and 50 mM NVP.
cDNA Quantification by Real-Time PCR
Levels of RT-generated EMCV cDNA were quantified by real-
time PCR in the TaqMan
TM format. Briefly, 10 ml of RT-
generated EMCV cDNA were added to 40 ml of PCR buffer
containing 16 AmpliTaq Gold buffer, 4.0 mM MgCl2, 250 mM
dNTP, 0.5 mM sense primer EMCF1 (59-CTCCCAT-
CAGGTTGTGCAGCGACC-39), 0.5 mM antisense primer
262R, 0.192 mM FAM-labeled probe 158T (59-AAGGTGAGAG-
CAAGCCTCGCAAAGACA-39), and 0.05 U 6 ml
21 AmpliTaq
Gold polymerase. The PCR reaction mixtures were then subjected
to 45 cycles at 95uC for 15 s and 60uC for 1 min. Oligonucleotides
EMCF1 and 262R, as well as the probe 158T were obtained from
Scientific Resources Program, CDC.
Measuring Enzymatic RT Resistance to Lamivudine and
Nevirapine
Susceptibility of HIV-1 RT for 3TC-TP or NVP was measured
by comparing the level of inhibition of the Amp-RT signal in
reactions done in the presence of drug relative to reactions without
drug. Samples were categorized as sensitive or resistant based on
the differences in Ct values (DCt) seen in reactions done in the
presence and absence of drug. One screening concentration was
established for 3TC and NVP based on the results from the 140
samples tested unblinded. The screening concentration was
selected to best differentiate in ‘‘sensitive’’ and ‘‘resistant’’
corresponding to the respective genotype. We considered only
samples that had an average Ct0 value below 36.25 cycles to
prevent misinterpretation of resistant samples because of signal
instability close to the detection limit. Samples with enzymatic
susceptibility data that did not correlate with resistance mutations
were tested further to determine Amp-RT IC50 and IC90 values.
To this end we applied inhibitor concentrations ranging from 5 to
500 mM, depending on the DCt obtained with 50 mM inhibitor
concentration. IC50 values were determined by linear regression.
Statistics
Statistical evaluation and graphic representation of the data was
done with with GraphPad Prism 4 (GraphPad Software Inc.,
USA). We derived DCt cut-off values for differentiating between
sensitive and resistant from the 140 samples tested unblinded for
validation. For 3TC and NVP we defined the cut off value as the
mean DCt of all genotypically resistant specimens using the
screening concentrations for 3TC and NVP plus 36the standard
deviation.
Results
Correlation between RT Levels by Amp-RT and RNA Virus
Loads
We first tested 140 clinical isolates with known RT genotypes.
The median log10 RNA virus loads of the 114 subtype B samples
was 4.260.8 log10 (range 2.4–5.5) and correlated well with the Ct
values determined by Amp-RT (r=0.68, 95% confidence interval,
0.77–0.57, P,0.0001). A similar correlation between the median
log10 RNA virus loads and Ct values measured Amp-RT was seen
in the 26 non-B subtypes samples (r=0.69, 95% CI interval, 0.85–
0.41, P,0.0001), illustrating that Ct values measured by Amp-RT
represent a good indication of plasma virus loads. (data not
shown). The specificity of the assay was evaluated by testing 160
samples from HIV-seronegative blood donors. The results showed
a mean Ct0 value of 44.661.1 (range 40.2, .45). A similar mean
Ct0 value (43.861.9, range 39.6245) was seen in 15 HIV-
seropositive specimens that had undetectable RNA virus loads
(,50 Geq6ml
21). Sixty control reactions done in the absence of
RT enzyme yielded no signal within 45 PCR cycles. Thus, no
RNA-negative sample yielded lower Ct values than the threshold
for clinical samples to be included in the resistance evaluation
(36.25).
Detection of 3TC and Nevirapine Resistance
We next evaluated the ability of the assay to discriminate
between 3TC- and NVP-sensitive and resistant viruses. Figure 1
shows the differences of Ct values (DCt) for 3TC and NVP seen in
all the isolates tested unblinded. The mean DCt for 3TC in 56 WT
isolates was 6.262.5 (range 0.29–11.2) and was significantly higher
(P,0.0001) than the mean DCt seen in the 55 3TC-resistant
isolates that had the M184V mutation (0.260.8, range -1.6–2.1,
Figure 1A). Figure 1B shows that the mean DCt for NVP seen in
83 WT isolates was 7.4263.18 (range 0.235–15.9) compared to a
mean DCt value of 0.48460.963 (range -1.85–2.15) seen in 28
NVP-resistant samples carrying K103N, Y181C/I, Y188L, or
G190A/Q (P,0.0001). These findings confirm that a single drug
concentration of 50 mM 3TC or NVP can reliably differentiate
between WT and resistant isolates as a screening assay.
We next selected the respective DCt cut-off values based on the
mean DCt+3.0 SD observed in all the mutant isolates, resulting at
2.66 and 3.28 for 3TC and NVP. Using these DCt cut-off values,
we found a very high concordance between Amp-RT phenotype
and RT genotype. For instance, all 55 samples that had M184V
were classified as 3TC-resistant while all 28 samples carrying
NVP-associated mutations were considered NVP-resistant. On the
other hand, 52 of the 56 samples with 184 M (92.9%) were
interpreted 3TC-sensitive, while 79 of the 83 samples lacking
detectable NVP-associated mutations (95.2%) were classified as
NVP-sensitive. Of the 8 discordant samples (4 for 3TC and 4 for
NVP), five had DCt values close to the assay cut-offs (data not
shown).
Assay Variability
We evaluated inter-assay variability of DCt values by comparing
the values observed in our control WT, 3TC- and NVP-resistant
isolates tested in 14 independent experiments. The DCt values for
HXB2 WT ranged from 7.9 to 10.8 with a mean of 9.5 for 3TC,
and from 7.9 to 11.9 for NVP (mean 9.73). The 3TC-resistant
control strain M184Vpitt yielded a mean DCt of 0.9 (range 0.3–1.6)
for 3TC and 8.8 for NVP (range 6.9–11.0). On the other hand the
NVP-resistant strain Y188C X403-4 resulted in a mean of 8.4
(range 6.9–9.7) for 3TC and 1.9 (range 1.3–2.7) for NVP. The
variability was much lower than the DCt cut-off values for the
Rapid Resistance Testing for HIV RT Inhibitors
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sensitive because of assay variation.
Assay Performance on Clinical Samples
We analyzed 173 specimens blinded, with genotypes revealed
only after the testing. Applying our previously defined cut-off
values, 99 samples were classified as 3TC-sensitive and 74 as 3TC-
resistant (Table 1) by Amp-RT. Of the 99 samples 3TC-sensitive
by Amp-RT, 94 (96%) were genotypically WT, 3 had a mixture of
M184 M/V, and 2 showed M184 V. The two samples with
M184 V had DCt values of 2.7 and 2.8, which were close to the
assay cut-off (2.66). Of the 8 samples that had an M184 M/V
mixture, 5 were Amp-RT resistant and 3 had DCt values below
4.1. Of the 74 samples with phenotypic resistance to 3TC, 70
(94%) had the M184 V or M184I mutations. Among these
samples, there were 64 184 V, 1 had 184I, and 5 had 184 V/M
mixtures. In four samples, phenotypic resistance to 3TC was seen
in the absence of detectable 184 V or 184I. We tested two of them
(DCt values 0.8 and 1.2) with higher 3TC concentrations (150,
500, and 1000 mM). The results further confirmed reduced 3TC
susceptibility in these two isolates (data not shown). However, the
levels of 3TC resistance were lower than those seen in an isolate
carrying the 184 V mutation. In three of the four strains with
reduced enzymatic susceptibility to 3TC in the absence of 184I/V
we found the mutation V118I which has been previously
associated with low-level enzymatic resistance to 3TC-TP [22].
Of the 173 samples tested for NVP resistance, 82 were classified
as sensitive and 91 as resistant. Enzymatic NVP resistance was
associated with the presence of K103N, Y181C/I, Y188L,
G190A/Q, or K238N in 88 of the 91 samples. The other 3
samples showed NVP resistance in the absence of any of these 5
mutations. Seventy-three of the 82 samples classified as NVP
sensitive had WT genotypes. Of the other remaining 9 samples, 2
had the K103N mutation and a DCt value close to the assay cut-
off (3.8 and 3.4), and 7 had mixtures of WT and mutant
genotypes. Overall, the current findings demonstrate the ability of
the new Amp-RT format to detect phenotypic resistance to 3TC
or NVP.
Assay Performance on Bead-Captured HIV-1
We also tested 162 blinded samples with a simplified protocol
replacing ultracentrifugation by concentrating the virus with
CD44-coated magnetic beads (mMultiMACS
TM VitalVirus HIV
Isolation Kit). The summarized results are illustrated in scatter
plots in Figure 2. Our cut-off values categorized the samples as
shown in Table 2. Of 110 samples categorized sensitive for 3TC
by Amp-RT only one had the mutation M184V, the correspond-
ing DC of 2.79 was only slightly above the cut-off (Figure 2A).
Conversely, 52 were enzymatically resistant to 3TC with 51 strains
harboring M184V. For NVP 102 specimens were Amp-RT
sensitive (Figure 2B). No NVP resistance mutation had been found
in 95, one had a mixed genotype K103 K/N and 6 contained the
mutations K103N, G190A, or Y188L. Four of the six samples
were further analyzed with different NVP concentrations to allow
for IC50 determination. Fold changes in IC50 values relative to
WT HIV-1HXB2 were 9.8, 6.4, 3.4, and 1.0 indicating enzymatic
NVP resistance for three 3 of 4 specimens. Fifty-nine specimens
were found to be enzymatically NVP-resistant. Of these, 56 had
NNRTI mutations and 3 had no NNRTI-resistance mutations. In
summary, there was a good correlation between genotype and
enzymatic resistance in both formats of virus preparation.
Discussion
Current treatment guidelines in the developed world recom-
mend the use of drug-resistance testing for the management of
patients receiving antiretroviral therapy. However, because such
testing relies mainly on sequencing or recombinant virus
phenotyping, which are costly and complex, it has remained
largely unavailable for the vast majority of patient populations
receiving ART in resource-limited settings. Thus, simpler and less
expensive drug resistance technologies may improve patient
management. Previously explored technology relied on detecting
and phenotyping HIV-associated RT activity in plasma by
ultrasensitive biochemical assays [9,17,23,24]. In this study we
describe an improved biochemical approach to resistance testing
for NNRTI and 3TC/FTC. The principle is based on our
previously reported Amp-RT assays [9,17] but has been improved
in two major ways. First, we include real-time PCR for the
detection of Amp-RT product which eliminates the need of ELISA
quantitation of the PCR products, thus reducing time and cost.
Secondly, we describe a method of HIV capture from plasma by
magnetic beads, eliminating the need for ultracentrifugation and
reducing cost and complexity.
Conventionally, phenotypic resistance is reported as fold
changes in IC50 values over a reference WT virus. Since this
approach requires testing of multiple drug concentrations we
sought to evaluate a screening method with only one drug
Figure 1. RT inhibition in 140 clinical isolates after virus concentration by ultracentrifugation. Genotypes had been classified into wild
type and mutant. Scatter plots show delta Ct values (threshold cycle difference between inhibited and uninhibited reaction) measured with 50 mM
3TC (A) and NVP (B). Horizontal bars indicate the respective mean values and the 95% confidence intervals. For mutants delta22Ct values are close to
0 for both drugs illustrating that mutant RT enzymes are virtually not inhibited by 50 mM drug concentrations.
doi:10.1371/journal.pone.0022019.g001
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that this approach was feasible, given the high level of resistance
conferred by M184V and many NNRTI mutations. By testing
large numbers of mutant and WT clinical specimens we show here
that inhibition with the 50 mM screening concentration correlated
well with the absence of genotypic markers of resistance to 3TC/
FTC. This screening concentration is close to the 3TC-TP
concentration that inhibits WT enzymatic activity by 100%
(IC100). We demonstrate that enzymatic 3TC resistance was
strongly associated with M184I/V. In addition, we also found that
the mutation V118I was associated with enzymatic 3TC resistance
in the absence of M184V in 3 of 4 cases. In vitro, V118 is reported
to confer resistance to 3TC and other nucleoside analogues only in
combination with other mutations like D67N and T215Y [22].
However, consistent with our results, Girouard and colleagues
detected a 21.7-fold enzymatic resistance to 3TC-TP in RTs
harboring just V118I [25]. The clinical significance of this
resistance is unclear and requires more study. NNRTI mutations
are common in ART-treated populations. Our data also show that
the screening Amp-RT format detecting resistance to NVP
correlated with the presence of K103N, Y181C/I, Y188L, and
G190A/Q. Thus, all primary mutations conferring resistance to
NNRTIs are detected. While K103N or Y188L confer high cross-
resistance between NVP and EFV[7], Y181C/I/V is associated
with only moderate resistance to EVF. Thus, the use of NVP in the
assay allowed the detection of resistance mutations that may be
selected by either NVP or EFV. However, further work may be
needed to determine if EFV is more suitable than NVP for
detecting resistance by particular NNRTI mutations that confer
higher resistance to EFV than NVP and whether the use of EFV
would have detected resistance in few mutant samples that showed
WT results in the current assay.
Despite the strong correlation between genotype and enzymatic
resistance, few specimens showed discrepant results. The reasons
for the discrepancies are not clear but could be related to a
number of factors including a wrong genotype because of
sequencing error, imperfect cut-offs values, mutations currently
not known to cause enzymatic resistance, or mixed genotypes that
are inconsistently detected genotypically or enzymatically. While
enzymatic IC50 determination clarified the discrepancies in many
samples, further phenotypic testing by culture-based methods and
additional genotypic analysis by ultradeep sequencing for minority
or mixed resistance, and inclusion of mutations in the connection
domain in RT that confer NNRI resistance could help resolve the
source of the residual discrepant results [26].
Although this work has focused on assays for 3TC/FTC and
NNRTI resistance because of the high prevalence in virologic
failure and the high level of resistance, this testing approach can be
adapted to other RT inhibitors, including new-generation
NNRTIs and other nucleoside analogs. Such assays will require
careful development that takes into account the level of enzymatic
resistance found in the mutants, and the need for a screening or
IC50-based testing format. One important improvement in our
testing is the capture of virus by magnetic beads, which eliminated
the need for ultracentrifugation and the associated cost, labor, and
maintenance. We demonstrate the utility of virus capture with
magnetic beads containing antibodies against CD44, a host-cell
protein that is commonly incorporated on the surface of HIV-1
particles. This method has the advantages of allowing high
throughput and automated processing. Overall, in contrast to
Table 1. Blinded drug-resistance testing with the 50 mM screening format after virus enrichment by ultracentrifugation.
3TC NVP
Genotype Wild type Mixed genotype Mutant
a Wild type Mixed genotype Mutant
b
Amp-RT sensitive 94 3 2 73 7 2
Amp-RT resistant 4 5 65 3 11 77
Total 98 8 67 76 18 79
aincluding the mutations M184V/I.
bincluding the mutations K103N, Y181C/I, Y188L, G190A/Q, or K238N.
doi:10.1371/journal.pone.0022019.t001
Figure 2. RT inhibition in 162 samples after virus concentration with CD44-coated beads. Genotypes had been classified into wild type
and mutant. Scatter plots show delta Ct values (threshold cycle difference between inhibited and uninhibited reaction) measured with 50 mM 3TC (A)
and NVP (B). Horizontal bars indicate the respective mean values and the 95% confidence intervals. The established cut-offs for both drugs classified
the isolates as summarized in Table 2. Data correlate well to those obtained by ultracentrifugation (Figure 1) with slightly more discrepancies
between geno- and phenotype for NVP.
doi:10.1371/journal.pone.0022019.g002
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the enzymatic Amp-RT testing described in this work does not
require special and expensive instrumentation or equipment but
instead a real-time PCR cycler and common equipment available
in clinical virology laboratories with biosafety level 2 capacity.
Additional studies geared to evaluating the assay in a resource-
limited setting would include further simplified storage conditions,
sensitivity to repeated freezing and thawing of the reagents and
interference with other infectious agents present in the samples.
The described assays have a short turnaround time and have the
advantage of being subtype-independent. The reaction carried out
in the absence of drug can also be used as a marker of virus load as
demonstrated in the good correlation with RNA loads in this and
previous studies [23]. In conclusion, we demonstrate the strong
potential for a simplified drug-resistance testing strategy based on
sensitive enzymatic assays for two key drug-resistance profiles that
are of particular importance for first-line regimens. Our data
strongly support expanded clinical evaluation and standardization
of this testing approach.
Acknowledgments
We are grateful to John Nkengasong (CDC, Atlanta) for providing the non-
B HIV sample set and to Sal Butera for advice in the use of magnetic
beads. Lamivudine and nevirapine were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID.
The findings and conclusions in this paper are those of the authors and
do not necessarily represent the views of the Centers for Disease Control
and Prevention.
Author Contributions
Conceived and designed the experiments: DH ADG PRH WH. Performed
the experiments: DH ADG. Analyzed the data: DH ADG. Contributed
reagents/materials/analysis tools: PRH ICDJ TN JGGL. Wrote the paper:
DH WH.
References
1. Richman DD (2001) HIV chemotherapy. Nature 410: 995–1001.
2. Deeks SG (2003) Treatment of antiretroviral-drug-resistant HIV-1 infection.
Lancet 362: 2002–11.
3. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al.
(2009) Update of the drug resistance mutations in HIV-1: December 2009. Top
HIV Med 17: 138–45.
4. EuroGuidelines Group for HIV Resistance (2001) Clinical and laboratory
guidelines for the use of HIV-1 drug resistance testing as part of treatment
management: recommendations for the European setting. The EuroGUidelines
Group for HIV resistance. Aids 15: 309–20.
5. Margot NA, Waters JM, Miller MD (2006) In vitro human immunodeficiency
virus type 1 resistance selections with combinations of tenofovir and
emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 50:
4087–95.
6. Wainberg MA, Hsu M, Gu Z, Borkow G, Parniak MA (1996) Effectiveness of
3TC in HIV clinical trials may be due in part to the M184V substitution in
3TC-resistant HIV-1 reverse transcriptase. Aids 10(Suppl 5): 3–10.
7. Bacheler L, Jeffrey S, Hanna G, D’Aquila R, Wallace L, et al. (2001) Genotypic
correlates of phenotypic resistance to efavirenz in virus isolates from patients
failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 75:
4999–5008.
8. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, et al. (2001)
Resistance profile and cross-resistance of HIV-1 among patients failing a non-
nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 65:
445–8.
9. Vazquez-Rosales G, Garcı ´a-Lerma JG, Yamamoto S, Switzer WM, Havlir D,
et al. (1999) Rapid screening of phenotypic resistance to nevirapine by direct
analysis of HIV type 1 reverse transcriptase activity in plasma. AIDS Res Hum
Retroviruses 15: 1191–200.
10. Barth RE, van der Loeff MFS, Schuurman R, Hoepelmon AIM, Wensing AMJ
(2010) Virological follow-up of adult patients in antiretroviral treatment
programmes in sub-Saharan Africa: a systematic review. Lancet Infectious
Diseases 10: 155–166.
11. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W (2010) Varied
Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy
in South Africa. Jaids-Journal of Acquired Immune Deficiency Syndromes 53:
480–484.
12. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, et al. (2006)
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose
zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic,
immunologic, and morphologic changes–a 96-week analysis. J Acquir Immune
Defic Syndr 43: 535–40.
13. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ (2009) Development
of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naive Subjects
on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared
With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934. J Acquir
Immune Defic Syndr.
14. Cheung PK, Wynhoven B, Harrigan PR (2004) 2004: which HIV-1 drug
resistance mutations are common in clinical practice? AIDS Rev 6: 107–16.
15. Heneine W, Yamamoto S, Switzer WM, Spira TJ, Folks TM (1995) Detection of
reverse transcriptase by a highly sensitive assay in sera from persons infected
with human immunodeficiency virus type 1. J Infect Dis 171: 1210–6.
16. Garcı ´a-Lerma JG, Soriano V, Mas A, Quinones-Mateu ME, Arts EJ, et al.
(2000) Quantitation of human immunodeficiency virus type 1 group O load in
plasma by measuring reverse transcriptase activity. Journal of Clinical
Microbiology 38: 402–405.
17. Garcı ´a-Lerma J, Schinazi RF, Juodawlkis AS, Soriano V, Lin Y, et al. (1999) A
rapid non-culture-based assay for clinical monitoring of phenotypic resistance of
human immunodeficiency virus type 1 to lamivudine (3TC). Antimicrob Agents
Chemother 43: 264–70.
18. Galli RA, Sattha B, Wynhoven B, O’Shaughnessy MV, Harrigan PR (2003)
Sources and magnitude of intralaboratory variability in a sequence-based
genotypic assay for human immunodeficiency virus type 1 drug resistance.
Journal of Clinical Microbiology 41: 2900–2907.
19. Tremblay MJ, Fortin JF, Cantin R (1998) The acquisition of host-encoded
proteins by nascent HIV-I. Immunology Today 19: 346–351.
20. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J (2009)
Analysis of the percentage of human immunodeficiency virus type 1 sequences
that are hypermutated and markers of disease progression in a longitudinal
cohort, including one individual with a partially defective Vif. J Virol 83:
7805–7814.
21. Lopez CA, Vazquez M, Hill MD, Colon MC, Porrata-Doria T, et al. (2010)
Characterization of HIV-1 RNA forms in the plasma of patients undergoing
successful HAART. Arch Virol 155: 895–903.
22. Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, et al. (2002) Broad
nucleoside-analogue resistance implications for human immunodeficiency virus
type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis 185:
898–904.
23. Garcia-Lerma JG, Yamamoto S, Gomez-Cano M, Soriano V, Green TA, et al.
(1998) Measurement of human immunodeficiency virus type 1 plasma virus load
Table 2. Blinded drug-resistance testing with the 50 mM screening format after virus enrichment by CD44-coated beads.
3TC NVP
Genotype Wild type Mixed genotype Mutant
a Wild type Mixed genotype Mutant
b
Amp-RT sensitive 109 0 1 95 1 6
Amp-RT resistant 1 0 51 3 0 56
Total 110 0 52 98 1 62
aincluding the mutations M184V/I.
bincluding the mutations K103N, Y181C/I, Y188L, G190A/Q, or K238N.
doi:10.1371/journal.pone.0022019.t002
Rapid Resistance Testing for HIV RT Inhibitors
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22019based on reverse transcriptase (RT) activity: evidence of variabilities in levels of
virion-associated RT. J Infect Dis 177: 1221–9.
24. Napravnik S, Cachafeiro A, Stewart P, Eron JJ, Jr., Fiscus SA (2009) HIV-1 viral
load and phenotypic antiretroviral drug resistance assays based on reverse
transcriptase activity in comparison to amplification based HIV-1 RNA and
genotypic assays. J Clin Virol 47: 18–22.
25. Girouard M, Diallo K, Marchand B, McCormick S, Gotte M (2003) Mutations
E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic
roles in dual resistance to AZT and 3TC. J Biol Chem 278: 34403–10.
26. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, et al. (2007) N348I in the
connection domain of HIV-1 reverse transcriptase confers zidovudine and
nevirapine resistance. Plos Medicine 4: 1887–1900.
Rapid Resistance Testing for HIV RT Inhibitors
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22019